NOV 10, 2020 8:45 AM PST

Liposomal Delivery Could Help Prevent Doxorubicin Cardiotoxicity

WRITTEN BY: Jasper Cantrell

One of the greatest failures of modern cancer therapies is the rather substantial off-target toxic effects many radio-, chemo-, and immunotherapies have. We have made great strides to improve these treatments but never-the-less struggle to get toxicity-free therapy to patients.

Cancer therapies range in methodology, mechanism of action, and effectiveness. Some therapies favor certain types of cancers, while others seem to affect a variety of cancers. Unfortunately, nearly all of these therapies essentially involve poisons that are designed to target cancer cells. As cancer cells are nearly identical to healthy cells in most ways, this often leads to off-target toxicities. These toxicities need to be accounted for before a patient engages in any specific treatment.

Breast cancer is one of the most common cancers in the world, with many well-studied treatments. One such treatment is doxorubicin, which unfortunately has some issues with cardiotoxicity. However, a newer version of doxorubicin using liposomal delivery (a type of delivery system using lipids) has shown to be less cardiotoxic than doxorubicin alone.

In a new study, a team from the Centre of Postgraduate Medical Education in Poland investigated how liposomal doxorubicin affected patient factors like overall survival and the amount of cardiotoxicity experienced. They did this by taking data from eight oncology centers in Poland and analyzing liposomal doxorubicin therapy results against other cancer therapies.

The team gathered data from 402 metastatic breast cancer patients, of which only 126 managed to complete their liposomal doxorubicin treatments. Analyzing these patients’ heart health and comparing them to patients treated with doxorubicin alone or other similar chemotherapies showed that liposomal doxorubicin was linked to a healthier heart after treatment. Overall survival comparison showed that only when liposomal doxorubicin was a secondary therapy or other specific incidences was there a significant difference.

With toxicity being a consistent issue with many cancer therapies, there is a keen interest in producing a therapy with little to no toxic side-effects. Liposomal doxorubicin is one such option, and this study found that it had lower cardiotoxicity than doxorubicin alone. This finding supports the use of liposomal doxorubicin in patients at a high risk of cardiovascular disease.

The team concludes that there needs to be more study, as several other factors increase cardiovascular disease incidence, such as diabetes.  The study concludes, “in patients with metastatic BC, prolonged liposomal doxorubicin treatment, i.e. lasting more than 3.5 months, and thus the administration of a higher cumulative dose, i.e. above 300 mg/m2, significantly increases OS.”

Sources: Nature Scientific Reports, British Heart Foundation

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
AUG 20, 2020
Cardiology
Cilia are Found to Have Vesicles That May Influence Heart Disease
AUG 20, 2020
Cilia are Found to Have Vesicles That May Influence Heart Disease
Cells have many specialized organelles, including a kind of signaling hub called a cilium, which sticks out of the surfa ...
SEP 03, 2020
Cardiology
Does Hypertension Make It Harder to Recognize Others Emotions?
SEP 03, 2020
Does Hypertension Make It Harder to Recognize Others Emotions?
Have you ever felt your blood pressure rise when you get angry or stressed? Well, this phenomenon is unique in that it l ...
SEP 08, 2020
Cardiology
Fixing Stem Cell Therapy for Heart Repair
SEP 08, 2020
Fixing Stem Cell Therapy for Heart Repair
Repairing the damage done by a heart attack has been of keen interest for decades. Some researchers think protecting the ...
DEC 03, 2020
Chemistry & Physics
3-D Printed, Realistic Heart Model for Training Future Physicians
DEC 03, 2020
3-D Printed, Realistic Heart Model for Training Future Physicians
Building a realistic tissue model is critical for training young physicians and surgeons, and yet challenging due to the ...
DEC 09, 2020
Immunology
Antibodies as Warning Signs of a Silent Cardiovascular Killer
DEC 09, 2020
Antibodies as Warning Signs of a Silent Cardiovascular Killer
In atherosclerosis, cholesterol and other fatty deposits build up around the inner walls of an artery, creating a plaque ...
JAN 07, 2021
Clinical & Molecular DX
Breath of Life: Nighttime Respiratory Rates Identify Which Heart Patients Need Surgery
JAN 07, 2021
Breath of Life: Nighttime Respiratory Rates Identify Which Heart Patients Need Surgery
Cardiovascular disease is the leading cause of death worldwide, taking nearly 18 million lives every year. Of these card ...
Loading Comments...